# VOR-001

Source: https://onco.cc/drugs/vor-001/  
OnCo record `vor-001` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VOR-001 is an oral medicine from Vortex Therapeutics designed to block the cancer-driving protein MYC directly; it has been tested in animals so far.

## Summary

VOR-001 is the lead programme of Vortex Therapeutics, described as an orally bioavailable small-molecule MYC inhibitor selected to advance to an investigational new drug application. The company reports nanomolar binding to MYC, tumour regression in a mouse hepatocellular carcinoma model and a predicted half-life of about 80 hours in preclinical models. No clinical trial is registered.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-04
- Tags: pipeline
- Code: VOR-001
- Modality: Oral small-molecule inhibitor
- Mechanism: Described by the company as a direct MYC inhibitor that binds a pocket formed when MYC is acetylated, selectively regulating MYC target genes.

## Sources

- Vortex Therapeutics pipeline: https://vortextherapeutics.com/pipeline-vortex-therapeutics/
- Vortex Therapeutics science: https://vortextherapeutics.com/science/

## Connected records

- targets: [MYC](https://onco.cc/targets/myc-gene/)
- companies: [Vortex Therapeutics](https://onco.cc/companies/vortex-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/vor-001.json